Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Alkermes Plc
(NQ:
ALKS
)
21.34
USD
-0.13 (-0.61%)
Streaming Delayed Price
Updated: 9:56 AM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Alkermes Plc
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
July 30, 2019
Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate,...
From
GlobeNewswire News Releases
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
July 30, 2019
-- Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events --
From
PR Newswire
Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
July 29, 2019
-- Patent Trial and Appeal Board Oral Hearing Cancelled --
From
PR Newswire
Alkermes Plc Reports Second Quarter 2019 Financial Results
July 25, 2019
-- Second Quarter Revenues of $279.9 Million, Primarily Driven by Approximately 24% Year-Over-Year Growth of Proprietary Product Net Sales --
From
PR Newswire
Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results
July 18, 2019
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, July 25, 2019, to discuss the company's second quarter 2019 financial...
From
PR Newswire
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
July 15, 2019
-- Following Pre-NDA Meeting With FDA, Company Plans to Submit New Drug Application for Schizophrenia and Bipolar I Disorder Indications in the Fourth Quarter of 2019 --
From
PR Newswire
Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History
July 01, 2019
Alkermes plc (Nasdaq: ALKS) today announced that for the 11th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the...
From
PR Newswire
Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
June 12, 2019
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage --
From
PR Newswire
New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
May 30, 2019
Biogen Inc. (Nasdaq: BIIB) announced today new interim data from the ongoing open-label, pivotal EVOLVE-MS-1 study indicate that the investigational treatment diroximel fumarate was generally well...
From
GlobeNewswire News Releases
Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual Meeting
May 22, 2019
-- New Safety and Tolerability Data to Be Presented From ALPINE Study of ARISTADA® and INVEGA SUSTENNA® in Patients With Schizophrenia --
From
PR Newswire
Alkermes to Present at the UBS Global Healthcare Conference
May 14, 2019
Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson, will participate in a fireside chat at the UBS Global Healthcare Conference on Monday,...
From
PR Newswire
Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences
May 13, 2019
-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings --
From
PR Newswire
Alkermes Plc Reports First Quarter 2019 Financial Results
April 25, 2019
-- First Quarter Revenues of $223.1 Million, Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales --
From
PR Newswire
Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing
April 24, 2019
Alkermes plc (Nasdaq: ALKS) today announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's...
From
PR Newswire
Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results
April 18, 2019
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, Apr. 25, 2019, to discuss the company's first quarter 2019 financial...
From
PR Newswire
Market Trends Toward New Normal in Granite Construction, Alkermes plc, Rexford Industrial Realty, Ultra Clean, Stellus Capital Investment, and Astronics — Emerging Consolidated Expectations, Analyst R
April 16, 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Granite Construction...
From
GlobeNewswire News Releases
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
April 09, 2019
-- Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study --
From
PR Newswire
Alkermes Announces Departure of Jim Robinson
April 08, 2019
Alkermes plc (Nasdaq: ALKS) announced today that Jim Robinson, President and Chief Operating Officer, has resigned from his position and will leave the company, effective April 19, 2019, for personal...
From
PR Newswire
Axonics® Appoints Nancy L. Snyderman, M.D. and Jane E. Kiernan to its Board of Directors
April 07, 2019
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the...
From
Business Wire News Releases
Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
April 03, 2019
-- The Second Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program Will Provide Funding for Up To Eight Research Projects With Individual Grant Amounts of Up To $100,000 per Project --
From
PR Newswire
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
April 01, 2019
-- Company to Host Investor Conference Call at 8:00 a.m. ET on Friday, April 12 --
From
PR Newswire
Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
March 20, 2019
The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new...
From
Business Wire News Releases
Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference
March 05, 2019
Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 39th Annual Health Care Conference on Tuesday, Mar. 12, 2019 at 8:40 a.m. ET...
From
PR Newswire
Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
February 27, 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunoco LP (NYSE:SUN),...
From
GlobeNewswire News Releases
Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors
February 25, 2019
-- Once-Weekly and Once-Every-Three-Week Dosing of ALKS 4230 to be Evaluated as Monotherapy and in Combination With Pembrolizumab --
From
PR Newswire
CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
February 25, 2019
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...
From
GlobeNewswire News Releases
CLASS ACTION UPDATE for YRIV, ALKS, MKL and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
February 25, 2019
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...
From
GlobeNewswire News Releases
CLASS ACTION UPDATE for DBVT, ALKS, GSM and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
February 25, 2019
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...
From
GlobeNewswire News Releases
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
February 24, 2019
Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate...
From
PR Newswire
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
February 24, 2019
Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for diroximel fumarate...
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.